Biocryst Pharmaceuticals (BCRX) EBIT (2010 - 2026)

Biocryst Pharmaceuticals has reported EBIT for 17 years, with the latest figure at -$701.6 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT fell 3405.22% year-over-year to -$701.6 million; the trailing twelve-month figure through Mar 2026 stood at -$381.8 million (down 1251.08% YoY), and the FY2025 full-year result was $341.0 million, up 13508.93% from the prior year.
• EBIT for Q1 2026 stood at -$701.6 million, down from $260.4 million in the prior quarter.
• The five-year high for EBIT was $260.4 million in Q4 2025, with the low at -$701.6 million in Q1 2026.
• Historically, EBIT has averaged -$36.2 million across 5 years, with a median of -$14.5 million in 2024.
• Annual changes were most pronounced in 2025 — EBIT surged 5876.06% — and 2026, when it tumbled 3405.22%.
• Biocryst Pharmaceuticals' EBIT stood at -$46.3 million in 2022, then advanced by 7.86% to -$42.7 million in 2023, then jumped by 89.44% to -$4.5 million in 2024, then surged by 5876.06% to $260.4 million in 2025, then plunged by 369.45% to -$701.6 million in 2026.
• The last three EBIT figures came in at -$701.6 million (Q1 2026), $260.4 million (Q4 2025), and $29.6 million (Q3 2025), per Business Quant data.